SLDB on Nasdaq

Solid Biosciences Inc.

American biological products company based in Charlestown.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with Evaxion A/S, CURIS INC or Taysha Gene Therapies, Inc., or pick any stock.

  • TickerSLDB on Nasdaq
  • IndustryBiological Products, (No Diagnostic Substances)
  • HeadquartersDE
  • Incorporated inDE2
  • Business address500 Rutherford Avenue, 3Rd Floor, Charlestown, Ma 021292
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-1315.2%Operating margin3
-1062.3%Net margin3
-40.6%Revenue growth, 20224
-40.6%Return on equity5
-$101.0MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Research and development100¢$78.4M

Out of $8.1M in revenue.43 The company lost money this year.

Financial statements

Revenue64$8.1M in 2022
0$5.0M$10.0M$15.0M2019: $0$020192020: $0$020202021: $13.6M$13.6M20212022: $8.1M$8.1M2022−41%
Operating income643-$106.5M in 2022−11% since 2019
-$150.0M-$100.0M-$50.0M02019: -$119.3M-$119.3M20192020: -$88.4M-$88.4M2020−26%2021: -$72.3M-$72.3M2021−18%2022: -$106.5M-$106.5M2022+47%
Net income743-$86.0M in 2022−27% since 2019
-$150.0M-$100.0M-$50.0M02019: -$117.2M-$117.2M20192020: -$88.3M-$88.3M2020−25%2021: -$72.2M-$72.2M2021−18%2022: -$86.0M-$86.0M2022+19%

Every line of the income statement as filed: the last 2 fiscal years, latest first.10

Period ending2025-12-312024-12-31
Research and development$140.3M$96.4M
General and administrative$38.9M$33.3M
Total operating expenses$179.2M$129.7M
Loss from operations-$179.2M-$129.7M
Interest income$9.9M$9.5M
Interest expense$203.0K-$340.0K
Change in fair value of derivative liabilities-$6.0M-$4.8M
Other income, net$824.0K$652.0K
Total other income, net$4.9M$5.0M
Net loss-$174.3M-$124.7M
Net loss per share, basic-$1.99-$3.06
Net loss per share, diluted-$1.99-$3.06
Weighted average shares of common stock outstanding used to compute basic net loss per share87.5M shares40.8M shares
Weighted average shares of common stock outstanding, used to compute diluted net loss per share87.5M shares40.8M shares

Compare Solid Biosciences Inc. with another company

Leadership

Who has led Solid Biosciences Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Ilan Ganot2018–2022
  2. Alexander Cumbo2022–now

President

  1. Gilad David Hayeem2018
  2. Ilan Ganot2018–2022
  3. Alexander Cumbo2022–now

Chief financial officer

  1. Jennifer Lynn Ziolkowski2019–2021
  2. Stephen J. Dipalma2021
  3. Kevin Tan2023–now

Chief operating officer

  1. Pedro Alvaro Amorrortu2018–2019
  2. Joel Solomon Zev Schneider2021–2022
  3. David T. Howton2023–now
20202025
Board members and other officers (29)

Former names

  • Solid Biosciences, LLCAug 4, 2017 to Jan 25, 20182

Timeline

  1. Dec 5, 2022New chief executive Alexander Cumbo becomes CEO12
  2. Jan 25, 2018New chief executive Ilan Ganot becomes CEO13

Filings

427 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 30 major events, 213 insider forms, 61 large holders, 1 private raises, 102 other. The latest 20:

  1. Oct 6, 20264 EDGAR
  2. Aug 14, 2026SCHEDULE 13D/A EDGAR
  3. Aug 14, 2026SCHEDULE 13G/A EDGAR
  4. Aug 6, 20268-K EDGAR
  5. Aug 6, 2026424B5 EDGAR
  6. Aug 6, 2026S-3ASR EDGAR
  7. Aug 6, 202610-Q EDGAR
  8. Aug 6, 2026SCHEDULE 13G EDGAR
  9. Jul 30, 2026SCHEDULE 13G EDGAR
  10. Jul 7, 20264 EDGAR
  11. Jun 24, 2026SCHEDULE 13D/A EDGAR
  12. Jun 24, 20263 EDGAR
  13. Jun 11, 20264 EDGAR
  14. Jun 11, 20264 EDGAR
  15. Jun 11, 20264 EDGAR
  16. Jun 11, 20264 EDGAR
  17. Jun 11, 20264 EDGAR
  18. Jun 11, 20264 EDGAR
  19. Jun 11, 20264 EDGAR
  20. Jun 11, 20264 EDGAR

The 427 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 61 such filings since October 2021, the latest 10:

  1. Aug 14, 2026SCHEDULE 13D/A
  2. Aug 14, 2026SCHEDULE 13G/A
  3. Aug 6, 2026SCHEDULE 13G
  4. Jul 30, 2026SCHEDULE 13G
  5. Jun 24, 2026SCHEDULE 13D/A
  6. May 5, 2026SCHEDULE 13G/A
  7. Apr 27, 2026SCHEDULE 13G/A
  8. Mar 17, 2026SCHEDULE 13D/A
  9. Mar 11, 2026SCHEDULE 13D/A
  10. Mar 10, 2026SCHEDULE 13D/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Dec 2, 2022Raised $9.2 million in a private offering of equity Form D: 13 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Ra Capital Management, L.P.12,036,126$120.2M1.0%+2,696,148
Perceptive Advisors LLC11,906,646$118.9M1.9%No change
Bain Capital Life Sciences Investors, LLC9,808,819$98.0M5.8%No change
Siren, L.L.C.7,690,405$76.8M1.6%No change
BlackRock, Inc.6,934,248$69.3M0.0%+1,975,894
Fmr LLC6,875,957$68.7M0.0%+3,269,553
Armistice Capital, LLC4,278,000$42.7M1.2%+1,078,000
State Street Corp4,175,365$41.7M0.0%+3,049,878
Jupiter Topco LLC4,043,605$40.4M0.0%New
Vanguard Capital Management LLC4,009,922$40.1M0.0%+1,335,298
Rtw Investments, LP3,892,926$38.9M0.3%New
Deep Track Capital, LP3,565,062$35.6M0.5%No change
Franklin Resources Inc3,440,708$34.4M0.0%+1,247,771
Citadel Advisors LLC2,815,122$28.1M0.0%+218,322
Alyeska Investment Group, L.P.2,280,484$22.8M0.1%+359
Ameriprise Financial Inc2,225,783$22.2M0.0%−213,066
Vestal Point Capital, LP2,160,000$21.6M0.5%−2,840,000
Redmile Group, LLC1,948,695$19.5M1.3%−63,200
Geode Capital Management, LLC1,940,824$19.4M0.0%+644,840
Goldman Sachs Group Inc1,602,917$16.0M0.0%+667,382
Adage Capital Partners Gp, L.l.c.1,506,506$15.0M0.0%−250,000
Dimensional Fund Advisors LP1,266,290$12.6M0.0%+310,155
Blair William & Co/il756,277$7.6M0.0%+105,061
Vanguard Portfolio Management LLC748,589$7.5M0.0%+409,959
Woodline Partners LP674,076$6.7M0.0%+179,000

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47